Strategies for implementation of guideline recommended cardiovascular risk management for patients with rheumatoid arthritis: results from a questionnaire survey of expert rheumatology centers

It has already been known for decades that patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular diseases (CVD), such as myocardial infarctions, cerebrovascular accidents, and congestive heart failures compared with the general population [1‐3]. Despite this, not much attention has been given to this patient group regarding CVD prevention [4, 5].

Therefore international guidelines have been developed, such as the guidelines of the American College of Cardiology (ACC) and American Heart Association (AHA) [6‐8], the European Society of Cardiology (ESC) guidelines for cardiovascular risk management (CVRM) [9, 10], and the European League Against Rheumatism (EULAR) recommendations for CVRM in patients with RA and other forms of inflammatory joint diseases [11, 12]. These guidelines state that besides optimal control of disease activity to lower CVD risk, regularly CVD riskassessment is recommended for all patients with RA. The present assessment of CVRM consists of screening of five traditional CVD risk factors (CVD-RFs): blood pressure, blood glucose, lipid profile, smoking status and body weight. Following the assessment of CVD-RFs, CVD preventive treatment should be initiated, if indicated. In addition to pharmacological therapy, lifestyle modification including a healthy diet, physical activity and smoking cessation should be supported [12].

These CVRM guidelines, and guidelines in general, are intended to improve the quality of care. They are mainly written to make the rapidly growing (scientific) information flow manageable; to reduce variation in actions between healthcare providers; to base clinical actions more on scientific evidence and to work more transparently [13]. However, a literature search indicates that CVRM guidelines as well as guidelines in general are not applied effectively in routine clinical practices [14‐16]. Percentages of patients with RA of whom CVD-RFs are identified vary between 24.9 and 88% [15, 17]. This variation in guideline adherence may be related to the different strategies used to implement CVRM in daily care. CVRM can be improved when rheumatology centers could learn from each other by comparing their daily CVRM care with others who have proved to work according to the recommendations. However, until now, it is unknown which approaches are used to organize CVRM according to the recommendations. This questionnaire survey is the first step to clarify this variation by identifying various systems for CVD risk evaluation and management in patients with RA in rheumatology expert centers across the world.

To evaluate differences in the organization of CVRM in patients with RA, we took advantage of two already existing networks in rheumatology. A questionnaire covering aspects of CVRM was sent by an email in 2017 to all members of both A TransAtlantic CVD risk Consortium for patients with RA (ATACC-RA, www.​atacc-ra.​com), and to the Survey of CVD Risk Factors in patients with RA (SURF-RA) audit group. ATACC-RA was formed in 2013 and includes 18 rheumatology centers from 13 countries [18]. The main aim of the ATACC-RA is to evaluate the burden of CVD in rheumatic and musculoskeletel diseases (RMD) to increase awareness of CVD and to develop implementation strategies to improve the care for patients with RMD. The SURF-RA is a large international survey including centers from 19 countries across the world that systematically examines the recording and control of CVD-RFs in patients with RA [18]. Topics covered in the questionnaire (see supplementary material 1) sent out to the centers were: (1) organization and responsibility of CVRM; (2) screening of traditional CVD-RF; (3) current CVRM status; and (4) availability of data regarding CVRM. Independent of each other, one researcher (JW) and one rheumatologist (PR), read the returned questionnaires and categorized clinics based primarily on which healthcare professionals were involved in CVRM. Afterwards, they discussed their findings and reached consensus about the different categories. This study was submitted to the local Ethics Committee Arnhem-Nijmegen and it was judged that the study did not fall within the scope of the Medical Research Involving Human Subjects Act (number 2020-6133). To ensure the privacy of the respondents, researchers worked with anonymized data. Furthermore, it was guaranteed that the data were not published with recognizable rheumatology centers.

This report describes three different strategies to implement guideline recommended CVRM for patients with RA in daily care. Adequate CVRM implies screening, appropriate lifestyle and pharmacological treatment of identified CVD-RFs to specific targets and follow-up to confirm that targets have been reached. Screening for the presence of CVD-RFs is not sufficient in itself, without sufficient subsequent action, to reduce the increased risk of CVD in patients with RA. As with the majority of studies, the design of the current study also contains limitations. The first limitation is that this study does not contain information on the outcomes of CVRM as this was outside the scope of this survey. Our survey was confined to identify the systems of CVRM and did not contain information on the results of CVRM. Due to practical (e.g. data stored in different software programs or only applicable on paper) and ethical reasons, it was not possible for the respondents of the survey to share their data related to results of CVRM. However, to our knowledge this is the first study that focused on the organization of care related to CVRM in patients with RA.

In both United States and Europe, patients with RA receive suboptimal care for their increased risk of CVD [15, 17]. Members of the ATACC-RA group are presumably particularly motivated and interested in CVRM, and the majority of respondents had a system for CVRM in place and followed international guidelines for CVRM. Almost all respondents reported that they performed screening of CVD-RFs at the first rheumatology outpatient consultation or soon after the diagnosis of RA was established. However, it is also important that both CVD-RFs assessment and intervention outcomes are regularly monitored and evaluated. In some rheumatology centres, there may be well room for improvement in follow-up of CVD-RFs assessment after screening.

The second limitation is the relatively low number of rheumatology centers that responded to the questionnaire. This might have an impact on the representativeness of the results. However, saturation of the answers to the questions was reached and each strategy to organize CVRM was reported at least thrice. Therefore, it is unlikely that a major strategy for CVRM was missed.

To date, it remains unclear which strategy results in the best adherence to international guidelines on CVRM. To compare the effectiveness of the various strategies of CVRM, data about CVD-RFs, treatment and outcomes are necessary. The overarching principle in the 2016 EULAR recommendations for CVD risk management is that the rheumatologist is responsible for CVD risk management in patients with RA and other inflammatory rheumatic diseases [12]. We advocate to optimize CVRM and to compare various strategies, a systematic recording of CVD-RF screening, treatment and targets in the medical files should be introduced in each rheumatology outpatient clinic and comparative audits could be performed. To a certain extent, this task is currently being undertaken by the international SURF-RA audit (www.​atacc-ra.​com). The impact of national health care system configuration and resources available to achieve CVRM must also be accurately assessed as this might have an impact on the results as well.

Independent of how CVRM is organized, adequate communication and feedback between the medical professionals involved and preferably also with the patients are of paramount importance. Each strategy may have advantages and disadvantages in this respect. In strategies involving the rheumatology team being solely responsible for CVRM, communication with other health professionals may appear of less importance, but the team must be aware of their knowledge and expertise limitations regarding CVRM and seek appropriate advice or onward referral when necessary. Strategies involving combined cardio-rheuma clinics have obvious potential advantages in terms of interdisciplinary communication and available expertise. However, in some countries or rheumatology centers, this strategy might be not possible due to either financial or staff shortage. Cardio-rheuma clinics may not be feasible in all healthcare systems and their clinical efficacy needs to be balanced against healthcare costs. Effective communication is of extreme importance in strategies where each healthcare professional (i.e. rheumatology, primary care and cardiology) has distinct responsibilities.

Independent of the various strategies developed by the different health care teams, relevant patient education may enable patients to play an active role by directly discussing the importance of adequate CVRM with their caregivers and initiate appropriate CVRM [19]. This may also have additional benefits where lifestyle modification is concerned [20].

This study identified three strategies to implement these CVRM in daily clinical practice based on who is primarily performing CVRM: the rheumatologist, a cardio-rheuma-clinic/team or the GP. Their relative merits and drawbacks should be prospectively assessed in future studies.